



Dedicated To Life

January 30, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated January 30, 2024 titled **“Zydus Lifesciences launches Rexigo™, the oral once-a-day pill for advanced prostate cancer patients in India”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus Lifesciences launches Rexigo™, the oral once-a-day pill for advanced prostate cancer patients in India

- *Rexigo™ (Relugolix) is a critical therapy as it suppresses testosterone in patients with advanced prostate cancer.*
- *Rexigo™ is the first generic, oral, once-a-day pill, making it much easier for patients. In the absence of this, patients needed to take injections.*
- *The drug's better cardiovascular safety profile helps elderly patients with comorbidities*
- *Brings in both access and affordability, as previously, it had not been made available in India despite being launched globally.*

Ahmedabad, January 30, 2024

Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that it has launched Relugolix under the brand name, Rexigo™. This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India. Though Relugolix was available in developed countries since the last four years, patients in India did not have access to it. With this launch, Zydus brings both access to a critical therapy and also makes it affordable at a cost of Rs. 6995 per month which is 50% less than the currently available injectable options. The drug will be manufactured at the group's manufacturing premises. This marks a big leap forward in the management of prostate cancer as patients and doctors will have a new option which can offer convenience, safety and rapid action.

Prostate cancer is one of the leading cancers in men and more than 43000 cases were reported in India in 2022 as per the National Cancer Registry Program of India. Prostate cancer growth is majorly driven by the male hormone, testosterone, a member of 'Androgens'. So, one of the key strategies of prostate cancer management is 'Androgen Deprivation Therapy (ADT)' with a goal of suppressing testosterone levels. It can be achieved by surgery or by using drugs. The duration of ADT depends on the disease status. The drugs currently used for treatment are all injectables with different routes of administration (in muscle or under the skin) and could be done only under the supervision of a care giver.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878

Rexigo™ alleviates this need. With this, the treatment for prostate cancer in India can now be made completely oral, thus helping patients lead a better quality of life.

Relugolix, became the first and only oral option of ADT drugs known as gonadotropin releasing hormone (GnRH) analogues with its launch globally in 2020. It shows rapid testosterone suppression which can be sustained throughout the treatment period. It also has better safety profile for heart related adverse events. Testosterone recovery is faster once Relugolix is stopped, so it is beneficial to patients needing suppression only for a fixed duration as a part of their treatment plan.

Zydus is one of the leading players in the Oncology segment in India and has been at the forefront, launching several First-in-India biosimilars and therapies. With a highly specialized and patient centric approach, the company has been able to bring access and affordability in cancer therapies. Six of the eight oncology pillar brands are leaders in their respective categories.

About Zydus

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 25,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com

###



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878